FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, namely to antibody or antigen-binding fragment there of that binds to a human PD-1 receptor. There are also disclosed: nucleic acid molecule encoding said antibody, expression vector comprising said nucleic acid molecule, host cell expressing said antibody, pharmaceutical composition comprising said antibody. Method for producing said host cell, method of producing said antibody, method of inhibiting PD-1 activity by said antibody, method of treating a disease with said antibody are disclosed.
EFFECT: invention allows to effectively treat diseases associated with PD-1.
19 cl, 12 dwg, 5 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| MONOCLONAL ANTIBODIES WHICH SPECIFICALLY BIND TO THE BETA-CHAIN REGION OF THE TRBV-9 FAMILY OF THE HUMAN T-CELL RECEPTOR, AND METHODS FOR USE THEREOF | 2018 |
|
RU2711871C1 |
| HUMANISED ANTI-BETA 9 CHAIN ANTIBODIES OF HUMAN TRBV9 TKP FAMILY, AND METHODS OF USING | 2018 |
|
RU2712251C1 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
